Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. Issue 2 (February 2018)
- Record Type:
- Journal Article
- Title:
- Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis. Issue 2 (February 2018)
- Main Title:
- Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis
- Authors:
- Persico, Marcello
Rosato, Valerio
Aglitti, Andrea
Precone, Davide
Corrado, Mariano
Luna, Antonio De
Morisco, Filomena
Camera, Silvia
Federico, Alessandro
Dallio, Marcello
Claar, Ernesto
Caporaso, Nicola
Masarone, Mario - Abstract:
- Background: Direct antiviral agents (DAA) demonstrated high efficacy among HCV-infected patients in registered trials. Nevertheless, the impact of these therapies on liver stiffness measurement (LSM) and liver functionality in 'real-life' is not well-known. The aim of the present study was to evaluate the sustained virological response (SVR) impact on LSM and clinical parameters of DAA-therapy on a real-life population of HCV patients with F3/F4 fibrosis. Methods: A total of 749 HCV genotype 1–4 patients with F3/F4 hepatitis undergoing antiviral therapy were consecutively enrolled in four centres of hepatology in Italy. Clinical, biochemical and imaging data were collected at the baseline (T0), at the end of treatment (EoT) and after 12 weeks (SVR12). Results: Out of 749 patients, 69.7% were F4 and 30.3% were F3. SVR12 was reached in 97.5%. LSM significantly decreased from T0 to EoT ( P <0.001), whereas, it did not from EoT to SVR12 ( P = not significant). Moreover, in F4 no significant differences were found in Child and MELD between T0, EoT and SVR12 ( P = not significant). At the univariate analysis of clinical and liver parameters, baseline high glucose ( P <0.005), type 2 diabetes ( P <0.001), low alanine aminotransferase (ALT; P <0.001), low platelets ( P <0.005), and the presence of esophageal varices (EV; P <0.001) were found to be associated with a lack of a significant EoT LSM improvement. At multiple regression, ALT ( P <0.05), diabetes ( P <0.005) and EV ( PBackground: Direct antiviral agents (DAA) demonstrated high efficacy among HCV-infected patients in registered trials. Nevertheless, the impact of these therapies on liver stiffness measurement (LSM) and liver functionality in 'real-life' is not well-known. The aim of the present study was to evaluate the sustained virological response (SVR) impact on LSM and clinical parameters of DAA-therapy on a real-life population of HCV patients with F3/F4 fibrosis. Methods: A total of 749 HCV genotype 1–4 patients with F3/F4 hepatitis undergoing antiviral therapy were consecutively enrolled in four centres of hepatology in Italy. Clinical, biochemical and imaging data were collected at the baseline (T0), at the end of treatment (EoT) and after 12 weeks (SVR12). Results: Out of 749 patients, 69.7% were F4 and 30.3% were F3. SVR12 was reached in 97.5%. LSM significantly decreased from T0 to EoT ( P <0.001), whereas, it did not from EoT to SVR12 ( P = not significant). Moreover, in F4 no significant differences were found in Child and MELD between T0, EoT and SVR12 ( P = not significant). At the univariate analysis of clinical and liver parameters, baseline high glucose ( P <0.005), type 2 diabetes ( P <0.001), low alanine aminotransferase (ALT; P <0.001), low platelets ( P <0.005), and the presence of esophageal varices (EV; P <0.001) were found to be associated with a lack of a significant EoT LSM improvement. At multiple regression, ALT ( P <0.05), diabetes ( P <0.005) and EV ( P <0.05) were inversely associated with significant LSM reduction. Conclusions: Virological response to DAA is associated with fibrosis regression and recovery of liver functionality and this can be detected as early as EoT. HCV eradication is associated with a rapid and significant clinical improvement that lasts over time and seems to be negatively influenced by diabetes and EV. … (more)
- Is Part Of:
- Antiviral therapy. Volume 23:Issue 2(2018)
- Journal:
- Antiviral therapy
- Issue:
- Volume 23:Issue 2(2018)
- Issue Display:
- Volume 23, Issue 2 (2018)
- Year:
- 2018
- Volume:
- 23
- Issue:
- 2
- Issue Sort Value:
- 2018-0023-0002-0000
- Page Start:
- 129
- Page End:
- 138
- Publication Date:
- 2018-02
- Subjects:
- Antiviral agents -- Periodicals
Antiviral Agents -- therapeutic use
Virus Diseases -- therapy
Viruses -- drug effects
Antiviral agents
Periodical
Electronic journals
Periodicals
616.9106 - Journal URLs:
- http://www.intmedpress.com/General/showSectionSub.cfm?SectionID=2&SectionSubID=1&SectionSubSubID=1 ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.3851/IMP3186 ↗
- Languages:
- English
- ISSNs:
- 1359-6535
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17206.xml